Form 4: Dynavax Technologies Director Peggy V Phillips Reports Acquisition and Disposal of Shares

Director Peggy V Phillips reports acquiring 5,357 shares of Dynavax Technologies and disposing of 43,804 shares, along with being granted options to purchase 22,500 shares.

Summary

• On May 23, 2024, Peggy V Phillips, a director of Dynavax Technologies Corp, reported transactions involving the company's stock.
• Phillips acquired 5,357 shares of common stock.
• Phillips disposed of 43,804 shares of common stock.
• Phillips was also granted options to purchase 22,500 shares of common stock at an exercise price of $11.85, which will fully vest one year from the grant date (May 23, 2024), provided she continues to provide services to the company.
• These options expire on May 22, 2031.
• Phillips also holds restricted stock units (RSUs), each representing a contingent right to receive one share of DVAX Common Stock, which will fully vest one year from the date of grant, with a mandatory deferral of release six months and one day after she no longer provides services to the Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports both acquisition and disposal of shares, and the granting of stock options. Without additional context, it's difficult to determine the overall impact on investor sentiment.

Positives

• The granting of stock options to a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Negatives

• The disposal of 43,804 shares by a director could be interpreted negatively by investors, although the reason for the disposal is not specified.

Risks

• The vesting of the stock options and RSUs is contingent upon the director's continued service to the company, creating a potential risk if the director were to leave before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of stock options and RSUs is tied to the director's continued service to the company.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the transactions of company directors and their holdings in the company. It is important for investors to monitor these filings as they can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The size of the stock option grant and share transactions should be compared to those of directors at similar-sized biotechnology companies to assess whether they are typical.
• Companies like Moderna (MRNA) and BioNTech (BNTX) also have frequent Form 4 filings related to their executives and directors.

Stakeholder Impact

• Shareholders may be interested in the director's transactions as an indicator of management's confidence in the company.
• Employees may view the stock option grants as a positive sign of potential future growth.

Key Dates